thyroglobulin 英/,θaɪrə(ʊ)'glɒbjʊlɪn/ 美/,θaɪro'ɡlɑbjəlɪn/
释 义 n. [生化] 甲状腺球蛋白
例 句 Objective: To investigate the relations between level of thyroglobulin and thyroid stimulating hormone in pregnant women. 目的：探讨孕妇甲状腺球蛋白水平和促甲状腺素水平之间的关系。
antibody 英 /'æntɪbɒdɪ/ 美 /'æntɪ'bɑdi/
释 义 n. [免疫] 抗体
例 句 It marshals the same antibody response to both of them. 它对两者作出的抗体反应都是一样的。
作者： Eyun Songa
Persistence of thyroglobulin antibody (TgAb) during follow-up in patients with differentiated thyroid carcinoma (DTC) after complete removal of the thyroid tissue is a challenge for clinicians since TgAb can interfere with thyroglobulin (Tg) measurement which is the most sensitive marker for remnant thyroid. TgAb is present in 17%–25% of patients with DTC and is an important factor for assessing the dynamic risk stratification, as proposed by Tuttle et al. and adopted by the guidelines of the American Thyroid Association. According to this classification, patients with DTC who underwent total thyroidectomy (TT) followed by radioiodine (RAI) ablation and are positive for TgAb exhibit prognoses similar to those observed between the “excellent response” and “structural incomplete response” groups. However, long-term data regarding the natural course of TgAb titers in these patients (i.e., the disappearance of TgAb and factors affecting the timing of negative conversion) are limited. Previous studies have reported that a median of 2–3 years is required for negative conversion of TgAb. The thyroid gland is the only source of Tg and TgAbs are mostly produced by lymphocytes infiltrating the gland; therefore, complete elimination of the thyroid tissue by TT and subsequent RAI ablation of the remnant thyroid tissue results in a progressive decline in TgAb levels and eventually its disappearance. However, certain patients may remain positive for TgAb years after ablation even in the absence of evidence of structural disease (no evidence of structural disease, NESD). There are evidences that increased or stationary TgAb titers may be associated with persistence/recurrence of thyroid cancer. However, there is no consensus on whether or when to performe extensive and/or frequent imaging investigations to detect evidence for structural disease in patients persistently positive for TgAb during follow-up. To clarify this issue, the present study evaluated the time trends of TgAb in patients with papillary thyroid carcinoma (PTC) and NESD, who previously underwent TT and subsequent RAI ablation and aimed to identify predictive factors for the rate of negative conversion of TgAb.